[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339202-105":59,"doc-detail-339202-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","hyperactive-stat5-hijacks-t-cell-receptor-signaling-and-drives-immature-t-cell-acute-lymphoblastic-leukemia-research-article","Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia - Research Article","","T cell acute lymphoblastic leukemia (T-ALL) is a malignant, immature T cell cancer with limited understanding of how STAT5A/STAT5B hyperactivation functions downstream of IL7R. The study analyzes the clinically frequent STAT5BN642H driver in T cell development and compares it with STAT5A hyperactive transgenic mouse variants. Hyperactive STAT5 disrupts T cell development, promotes an early T cell progenitor–ALL phenotype, upregulates TCR signaling genes, and drives STAT5-dependent activation of the TCR pathway. Mechanistic validation includes STAT5 DNA binding by ChIP-Seq and sensitivity to dual STAT3/5 degraders and ZAP70 blockade in vitro and in vivo, supporting targeted therapy concepts.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hyperactive-stat5-hijacks-t-cell-receptor-signaling-and-drives-immature-t-cell-acute-lymphoblastic-leukemia-research-article/339202/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hyperactive-stat5-hijacks-t-cell-receptor-signaling-and-drives-immature-t-cell-acute-lymphoblastic-leukemia-research-article/339202.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the study focus on regarding STAT5 signaling in T-ALL?","Question",{"text":113,"@type":114},"It investigates how hyperactive STAT5, especially the frequent STAT5BN642H driver, controls T cell receptor (TCR) signaling and contributes to the onset of immature T cell leukemia.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does STAT5 hyperactivity alter T cell development in the reported models?",{"text":118,"@type":114},"Enhanced STAT5 activity disrupts normal T cell development and promotes an early T cell progenitor–ALL phenotype, including increased expression of TCR pathway genes.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports a therapeutic targeting strategy in the study?",{"text":122,"@type":114},"STAT5-dependent activation of TCR pathway kinases is validated, and human T-ALL cells show sensitivity to pharmacologic dual STAT3/5 degraders and ZAP70 tyrosine kinase blockers in vitro and in vivo.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339202,1790193913,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nHyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia  \nTobias Suske,1 Helena Sorger,1 Gabriele Manhart,2 Frank Ruge,1 Nicole Prutsch,3 Mark W. Zimmerman,3 Thomas Eder,2  \nDiaaeldin I. Abdallah,4,5 Barbara Maurer,1 Christina Wagner,1 Susann Schönefeldt,1 Katrin Spirk,1 Alexander Pichler,6 Tea Pemovska,6 Carmen Schweicker,6 Daniel Pölöske,1 Emina Hubanic,1 Dennis Jungherz,7 Tony Andreas Müller,7 Myint Myat Khine Aung,1  \nAnna Orlova,1 Ha Thi Thanh Pham,1 Kerstin Zimmel,1 Thomas Krausgruber,8,9 Christoph Bock,8,9 Mathias Müller,1 Maik Dahlhoff,10 Auke Boersma,10 Thomas Rülicke,10,11 Roman Fleck,12 Elvin Dominic de Araujo,4,5 Patrick Thomas Gunning,4,5,12 Tero Aittokallio,13,14,15,16 Satu Mustjoki,14,17,18 Takaomi Sanda,19 Sylvia Hartmann,20 Florian Grebien,2,21 Gregor Hoermann,22 Torsten Haferlach,22  \nPhilipp Bernhard Staber,6 Heidi Anne Neubauer,1 Alfred Thomas Look,3 Marco Herling,7,23 and Richard Moriggl1,24  \n1Institute of Animal Breeding and Genetics and 2Institute for Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, Austria. 3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. 4Department of Chemical and Physical Sciences, University of Toronto Mississauga, Mississauga, Ontario, Canada. 5Department of Chemistry, University of Toronto, Toronto, Ontario, Canada. 6Department of Medicine I, Clinical Division of Hematology, Medical University of Vienna, Vienna, Austria. 7Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, Cologne, Germany. 8CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. 9Institute of Artificial Intelligence, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria. 10Institute of in vivo and in vitro Models, University of Veterinary Medicine Vienna, Vienna, Austria. 11Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. 12Janpix, London, United Kingdom. 13Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland. 14iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. 15Department of Cancer Genetics, Institute for Cancer Research,  \nOslo University Hospital, Oslo, Norway. 16Oslo Centre for Biostatistics and Epidemiology, Faculty of Medicine, University of Oslo, Oslo, Norway. 17Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 18Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. 19Cancer Science Institute of Singapore and Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 20Dr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany. 21St. Anna Children’s Cancer Research Institute, Vienna, Austria. 22MLL Munich Leukemia Laboratory, Munich, Germany. 23Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Leipzig, Germany. 24Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.  \nT cell acute lymphoblastic leukemia (T-ALL) is an aggressive immature T cell cancer. Mutations in IL7R have been analyzed genetically, but downstream effector functions such as STAT5A and STAT5B hyperactivation are poorly understood. Here, we studied the most frequent and clinically challenging STAT5BN642H driver in T cell development and immature T cell cancer onset and compared it with STAT5A hyperactive variants in transgenic mice. Enhanced STAT5 activity caused disrupted T cell development and promoted an early T cell progenitor–ALL phenotype, wi","cbCaihVw5AInQLIM","https://ap.wps.com/l/cbCaihVw5AInQLIM","pdf",10087917,16,"English","# Introduction\n## Background of T-ALL and IL7R/STAT5 signaling\n## Study aim and experimental approach\n## Key findings: STAT5 hyperactivation and TCR pathway hijacking\n## Therapeutic implications and validation","[{\"question\":\"What does the study focus on regarding STAT5 signaling in T-ALL?\",\"answer\":\"It investigates how hyperactive STAT5, especially the frequent STAT5BN642H driver, controls T cell receptor (TCR) signaling and contributes to the onset of immature T cell leukemia.\"},{\"question\":\"How does STAT5 hyperactivity alter T cell development in the reported models?\",\"answer\":\"Enhanced STAT5 activity disrupts normal T cell development and promotes an early T cell progenitor–ALL phenotype, including increased expression of TCR pathway genes.\"},{\"question\":\"What evidence supports a therapeutic targeting strategy in the study?\",\"answer\":\"STAT5-dependent activation of TCR pathway kinases is validated, and human T-ALL cells show sensitivity to pharmacologic dual STAT3/5 degraders and ZAP70 tyrosine kinase blockers in vitro and in vivo.\"}]","Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia - Research Article | PDF",1790028587,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/739b9c6a46ae2847ca2c6ed468002c36.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d44b55b0876afc392c24131558316569.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/438e0c0509c8ce6a90dd3745a9ecac3b.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c056799a431d64e6bbfef7ac08d3d602.webp",980,1311]